Organogenesis (NASDAQ:ORGO) Shares Down 3.6% – What’s Next?

Organogenesis (NASDAQ:ORGO)’s share price fell 3.6% during trading on Friday. The stock traded as low as $0.9330 and last traded at $0.9932. 1,338,803 shares were traded during mid-day trading, an increase of 64% from the average daily volume of 815,558 shares. The stock had previously closed at $1.03.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Weiss Ratings cut shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Truist Financial dropped their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Finally, Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $4.33.

Organogenesis Trading Down 3.6%

The firm has a market capitalization of $127.80 million, a P/E ratio of -1.15 and a beta of 1.27. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.00 and a current ratio of 3.52. The firm has a 50 day moving average price of $1.45 and a two-hundred day moving average price of $2.07.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.36). The company had revenue of $43.76 million during the quarter, compared to analyst estimates of $54.27 million. Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%.

Hedge Funds Weigh In On Organogenesis

A number of institutional investors have recently bought and sold shares of ORGO. BlackRock Inc. acquired a new stake in Organogenesis during the 2nd quarter worth about $17,616,000. Dimensional Fund Advisors LP lifted its stake in Organogenesis by 5.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock valued at $6,851,000 after buying an additional 160,026 shares in the last quarter. Deutsche Bank AG purchased a new stake in Organogenesis during the second quarter valued at about $4,146,000. Renaissance Technologies LLC boosted its holdings in shares of Organogenesis by 30.5% in the first quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company’s stock worth $2,532,000 after buying an additional 249,838 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Organogenesis by 39.8% in the first quarter. SG Americas Securities LLC now owns 790,766 shares of the company’s stock worth $1,874,000 after buying an additional 225,265 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc (NASDAQ: ORGO) is a regenerative medicine company that develops, manufactures and commercializes advanced products designed to help repair and restore damaged tissue. Its principal business areas are advanced wound care and surgical and sports medicine, with products intended for use by hospitals, wound-care centers, physicians and other health care providers.

The company’s advanced wound-care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as Dermagraft, PuraPly and other biologic and synthetic products.